Acuitas Investments LLC Raises Holdings in Accuray Incorporated (NASDAQ:ARAY)

Acuitas Investments LLC boosted its stake in shares of Accuray Incorporated (NASDAQ:ARAY - Free Report) by 100.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,420,207 shares of the medical equipment provider's stock after buying an additional 711,654 shares during the period. Accuray accounts for 2.2% of Acuitas Investments LLC's investment portfolio, making the stock its 24th largest position. Acuitas Investments LLC owned 1.38% of Accuray worth $2,542,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. acquired a new stake in shares of Accuray during the 4th quarter worth approximately $35,000. Prudential Financial Inc. purchased a new position in Accuray in the fourth quarter worth approximately $43,000. ProShare Advisors LLC increased its stake in Accuray by 50.7% during the fourth quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider's stock worth $54,000 after acquiring an additional 9,187 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Accuray in the fourth quarter valued at $66,000. Finally, Gabelli Funds LLC lifted its stake in shares of Accuray by 12.5% in the 4th quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider's stock valued at $89,000 after purchasing an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 64.08% of the company's stock.

Accuray Stock Performance

Shares of ARAY traded up $0.03 during trading on Friday, reaching $1.42. 486,930 shares of the company traded hands, compared to its average volume of 774,100. The stock has a 50-day simple moving average of $1.44 and a 200-day simple moving average of $1.78. Accuray Incorporated has a twelve month low of $1.14 and a twelve month high of $2.95. The company has a debt-to-equity ratio of 3.35, a current ratio of 1.64 and a quick ratio of 0.92.

Accuray (NASDAQ:ARAY - Get Free Report) last posted its earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.04. The firm had revenue of $113.24 million during the quarter, compared to the consensus estimate of $101.53 million. Accuray had a net margin of 0.14% and a return on equity of 1.43%. Equities analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen raised Accuray from a "hold" rating to a "buy" rating in a research report on Friday, May 30th.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.